MIST
NASDAQMilestone Pharmaceuticals Inc.
Price$1.30-0.02 (-1.52%)
01:30 PM07:45 PM
News · 26 weeks52+14%
2025-12-282026-06-21
Mix2290d
- Insider8(36%)
- SEC Filings7(32%)
- Other4(18%)
- Earnings2(9%)
- Analyst1(5%)
Latest news
25 items- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- INSIDERSEC Form 4 filed by Director Wills Robert James4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Duty Stuart4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Papa Joseph C4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Saik Andrew4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Fischer Seth H. Z.4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Giles Lisa M.4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERSEC Form 4 filed by Director Tomsicek Michael John4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- SECSEC Form EFFECT filed by Milestone Pharmaceuticals Inc.EFFECT - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you
- SECSEC Form S-3 filed by Milestone Pharmaceuticals Inc.S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateCARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress toward broad patient accessAtrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational prioritiesCompany to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of
- SECSEC Form 10-Q filed by Milestone Pharmaceuticals Inc.10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Date:Wednesday, May 13, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13760062Webcast link:Click here. Participants can use Guest
- SECSEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECSEC Form DEF 14A filed by Milestone Pharmaceuticals Inc.DEF 14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- INSIDERSEC Form 4 filed by Oliveto Joseph4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- ANALYSTRaymond James initiated coverage on Milestone Pharmaceuticals with a new price targetRaymond James initiated coverage of Milestone Pharmaceuticals with a rating of Strong Buy and set a new price target of $6.00
- PRMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTMONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of CARDAMYST™ (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT). "Registry of Etripamil (CARDAMYST™) Studies Evaluating Treatment in Paroxysmal Supraventricular Tachycardia (RESET-PSVT): Study Design," was presented in a poster session at the Preventive Cardiovascular Nurses
- PRMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceMONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026. A webcast of the presentation will be available on April 13th at 3:45 PM EDT. The webcast will be available to watch here and there will be a replay for approximately 90 days on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference,
- PRMilestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesMONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the nation's largest pharmacy benefit managers, has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. This inclusion makes CARDAMYST broadly accessible and affordable for their commercially insured lives across the United States. CARDAMYST is the first and only self-administered nasal spray approved by the U.S. Food and Drug Administration (FDA) for the conversion
- INSIDERSEC Form 3 filed by new insider Sandoval David I.3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVTFDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE
MIST FAQ
7 questionsWhat does Milestone Pharmaceuticals Inc. do?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and...Where does MIST stock trade?
Milestone Pharmaceuticals Inc. (MIST) is listed on NASDAQ.What sector and industry is MIST in?
Milestone Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Milestone Pharmaceuticals Inc. go public?
Milestone Pharmaceuticals Inc. (MIST) completed its IPO in 2019.What are analysts saying about MIST?
Milestone Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $600.00 price target on 2026-04-10. Recent price targets range from $400.00 to $1000.00.What companies are similar to MIST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MIST side-by-side with any of them on Quantisnow.How can I track MIST on Quantisnow?
Quantisnow aggregates Milestone Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIST to receive live email and push alerts on every new disclosure.